Drug
Gadolinium
Gadolinium: highest development phase Post-Market, developed by Guerbet. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Guerbet
Trials
| Drug | Phase | Indication |
|---|---|---|
| Gadolinium NCT02530931 | Post-Market | Meniere's Disease |
Latest
No recent events.
Follow Gadolinium on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.